Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Income from Continuing Operations (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Income from Continuing Operations for 9 consecutive years, with 5747000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Income from Continuing Operations rose 38.83% year-over-year to 5747000.0, compared with a TTM value of 38521000.0 through Jun 2025, down 38.28%, and an annual FY2025 reading of 26736000.0, up 32.84% over the prior year.
  • Income from Continuing Operations was 5747000.0 for Q2 2025 at VYNE Therapeutics, up from 8603000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 5612000.0 in Q1 2023 and bottomed at 19924000.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 9412277.78, with a median of 8648500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations soared 88.1% in 2021, then plummeted 100.25% in 2024.
  • Year by year, Income from Continuing Operations stood at 8372000.0 in 2021, then rose by 7.3% to 7761000.0 in 2022, then increased by 20.74% to 6151000.0 in 2023, then crashed by 95.32% to 12014000.0 in 2024, then soared by 52.16% to 5747000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for VYNE at 5747000.0 in Q2 2025, 8603000.0 in Q1 2025, and 12014000.0 in Q4 2024.